Want FREE Templates on Organization, Change, & Culture? Download our FREE compilation of 50+ slides. This is an exclusive promotion being run on LinkedIn.

Market Overview: Multiple Myeloma   27-page PDF document
$299.00

Market Overview: Multiple Myeloma (27-page PDF document) Preview Image Market Overview: Multiple Myeloma (27-page PDF document) Preview Image Market Overview: Multiple Myeloma (27-page PDF document) Preview Image Market Overview: Multiple Myeloma (27-page PDF document) Preview Image Market Overview: Multiple Myeloma (27-page PDF document) Preview Image Market Overview: Multiple Myeloma (27-page PDF document) Preview Image Market Overview: Multiple Myeloma (27-page PDF document) Preview Image Market Overview: Multiple Myeloma (27-page PDF document) Preview Image Market Overview: Multiple Myeloma (27-page PDF document) Preview Image Log in to unlock full preview.
Arrow   Unlock all 10 preview images:   Login Register

Market Overview: Multiple Myeloma (PDF)

File Type: 27-page PDF document

#1 in Oncology $299.00

Add to Cart
  


BUY WITH CONFIDENCE

Immediate digital download upon purchase.
Lifetime document updates included with purchase.
Trusted by over 10,000+ organizations.

BENEFITS OF DOCUMENT

  1. The multiple myeloma market will witness an impressive 10% annual growth over 2015-2025
  2. Currently approved therapies will continue to have a meaningful impact on the multiple myeloma treatment algorithm and market sales
  3. Major-market sales increasing from $8.6 billion in 2015 to $22.3 billion in 2025

DESCRIPTION

This product (Market Overview: Multiple Myeloma) is a 27-page PDF document, which you can download immediately upon purchase.

The multiple myeloma market will witness an impressive 10% annual growth over 2015-2025, with major-market sales increasing from $8.6 billion in 2015 to $22.3 billion in 2025. Growth will be fueled by the continued uptake and label expansions of current therapies and the expected market entry of four novel, premium-priced therapies. Immunomodulatory agents are, and will remain, the dominant drug class throughout the forecast period and will capture more than 50% of major-market sales in 2025.

Currently approved therapies will continue to have a meaningful impact on the multiple myeloma treatment algorithm and market sales. Lenalidomide is set to retain its position as the sales-leading agent in multiple myeloma, with sales expected to reach more than $11.7 billion across the seven major markets in 2025. Continued penetration of the R/R setting will provide significant revenue, as will its label expansion in the first-line setting, in addition to use in combination with recently approved and emerging agents, such as carfilzomib, ixazomib, elotuzumab, daratumumab, and pembrolizumab.
Introduction
Key Findings
Market Share of Cancer Drug Classes in 2015 and 2025
Market SWOT Analysis
Etiology and Pathophysiology
Key Findings
Expert Insight
Pathophysiology
Anatomy
Subtypes
Staging and Classification
Key Pathways and Drug Targets
Market Outlook
Key Findings
Expert Insight
Market Overview
Market Drivers and Constraints
What Factors Are Driving the Market?
What Factors Are Constraining the Market?

Got a question about the product? Email us at support@flevy.com or ask the author directly by using the "Ask the Author a Question" form. If you cannot view the preview above this document description, go here to view the large preview instead.

Source: Best Practices in Healthcare, Cancer PDF: Market Overview: Multiple Myeloma PDF (PDF) Document, pharmzolgas


$299.00

Add to Cart
  

OVERVIEW

File Type: PDF pdf (PDF)
File Size: 1.9 MB
Number of Pages: 27

ABOUT THE AUTHOR

Author: pharmzolgas
Additional documents from author: 3

Ask the Author a Question

Must be logged in

Did you know?
The average daily rate of a McKinsey consultant is $6,625 (not including expenses). The average price of a Flevy document is $65.




Trusted by over 10,000+ Client Organizations
Since 2012, we have provided best practices to over 10,000 businesses and organizations of all sizes, from startups and small businesses to the Fortune 100, in over 130 countries.
AT&T GE Cisco Intel IBM Coke Dell Toyota HP Nike Samsung Microsoft Astrazeneca JP Morgan KPMG Walgreens Walmart 3M Kaiser Oracle SAP Google E&Y Volvo Bosch Merck Fedex Shell Amgen Eli Lilly Roche AIG Abbott Amazon PwC T-Mobile Broadcom Bayer Pearson Titleist ConEd Pfizer NTT Data Schwab




Read Customer Testimonials





Customers Also Like These Documents

Related Management Topics


Healthcare Cancer Integrated Financial Model ESG Scheduling Value Chain Analysis

Download our FREE Strategy & Transformation Framework Templates

Download our free compilation of 50+ Strategy & Transformation slides and templates. Frameworks include McKinsey 7-S Strategy Model, Balanced Scorecard, Disruptive Innovation, BCG Experience Curve, and many more.